As the clinical course of prostate cancer in men with LP/P BRCA1/2 variants may be worse, the detection of low-grade cancer in men with LP/P BRCA1/2 variants needs to be weighed against the treatment outcomes [22, 23]. This evidence concerns the gene BRCA1 and Familial prostate cancer.